Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases

Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases

Abstract Background Interstitial lung diseases (ILD) encompass a heterogenous group of diffuse parenchymal lung disorders characterized by variable degrees of inflammation and fibrosis. Pretherapeutic clinical testing models for such diseases can serve as a platform to test and develop effective the...

Full description

Bibliographic Details
Main Authors:	Kevin G. Dsouza, Ranu Surolia, Tejaswini Kulkarni, Fu Jun Li, Pooja Singh, Huaxiu Zeng, Crystal Stephens, Abhishek Kumar, Zheng Wang, Veena B. Antony
Format:	Article
Language:	English
Published:	BMC 2023-03-01
Series:	Respiratory Research
Online Access:	https://doi.org/10.1186/s12931-023-02404-7

Similar Items

Pathophysiological Role of Vimentin Intermediate Filaments in Lung Diseases
by: Ranu Surolia, et al.
Published: (2022-04-01)

Low dose cadmium exposure regulates miR-381–ANO1 interaction in airway epithelial cells
by: Pooja Singh, et al.
Published: (2024-01-01)

Antifibrotic therapies in rheumatoid arthritis associated interstitial lung disease
by: Cemal Bes, et al.
Published: (2022-07-01)

Antifibrotic in interstitial lung diseases: When, where, and how long?
by: Deependra K Rai, et al.
Published: (2022-01-01)

Interstitial lung diseases: the role of HRCT in in the era of antifibrotic therapy
by: Alfredo Nicodemos Cruz Santana, et al.
Published: (2020-11-01)

The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease
by: Minrui Liang, et al.
Published: (2022-02-01)

Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease
by: Erin M. Wilfong, et al.
Published: (2021-12-01)

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases
by: Sebastiano Emanuele Torrisi, et al.
Published: (2019-11-01)

Differences in the Evolution of Lung Function Before and After Treatment With Antifibrotics in Patients With Interstitial Lung Disease
by: Katiuska Herminia Liendo-Martínez, et al.
Published: (2023-10-01)

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD
by: John N. Shumar, et al.
Published: (2021-05-01)

Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
by: Atsushi Kumanogoh, et al.
Published: (2023-01-01)

Use of antifibrotic drugs in familial interstitial pneumonia: analysis of one family
by: Deborah dos Reis Estrella, et al.
Published: (2021-12-01)

A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities
by: Sahajal Dhooria, et al.
Published: (2022-01-01)

Antifibrotic Agents in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis
by: Ji Hoon Jang, et al.
Published: (2023-12-01)

Treatment with antifibrotic agents in idiopathic pleuroparenchymal fibroelastosis with usual interstitial pneumonia
by: Keishi Sugino, et al.
Published: (2021-03-01)

Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications
by: Gian Luca Erre, et al.
Published: (2021-01-01)

Impact of Antifibrotic Treatment on Postoperative Complications in Patients with Interstitial Lung Diseases Undergoing Lung Transplantation: A Systematic Review and Meta-Analysis
by: Pahnwat Taweesedt, et al.
Published: (2023-01-01)

Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects
by: Hideki Nawa, et al.
Published: (2022-12-01)

NETosis in the pathogenesis of acute lung injury following cutaneous chemical burns
by: Ranu Surolia, et al.
Published: (2021-05-01)

In Vitro and In Vivo Antifibrotic Effects of Fraxetin on Renal Interstitial Fibrosis via the ERK Signaling Pathway
by: Yi-Hsien Hsieh, et al.
Published: (2021-07-01)

HGF Expressing Stem Cells in Usual Interstitial Pneumonia Originate from the Bone Marrow and Are Antifibrotic.
by: Amiq Gazdhar, et al.
Published: (2013-01-01)

Erratum: Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group
Published: (2022-01-01)

Antifibrotics in India
by: Raja Dhar
Published: (2019-01-01)

The elusive antifibrotic macrophage
by: Adhyatmika eAdhyatmika, et al.
Published: (2015-11-01)

Pleiotropic antifibrotic actions of aspirin-triggered resolvin D1 in the lungs
by: Rafael F. Guilherme, et al.
Published: (2023-03-01)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
by: Bridget F. Collins, et al.
Published: (2019-10-01)

Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
by: Sachin Chaudhary, et al.
Published: (2020-09-01)

Antifibrotic drugs as therapeutic tools in resistant melanoma
by: Berta Sanchez‐Laorden, et al.
Published: (2022-03-01)

Deciphering the Antifibrotic Property of Metformin
by: Axelle Septembre-Malaterre, et al.
Published: (2022-12-01)

COVID-19-Associated Lung Fibrosis: Two Pathways and Two Phenotypes, Lung Transplantation, and Antifibrotics
by: René Hage, et al.
Published: (2022-07-01)

Corrigendum: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
by: Sachin Chaudhary, et al.
Published: (2021-03-01)

Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity
by: Hiroshi Takahashi, et al.
Published: (2021-08-01)

Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
by: Soroush Seifirad, et al.
Published: (2021-01-01)

Reactivation of tuberculosis in patient treated with the antifibrotic drug nintedanib
by: Iliya Iliev Krachunov, et al.
Published: (2022-01-01)

HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis
by: Xing Lyu, et al.
Published: (2019-07-01)

Antifibrotic therapy to normalize the tumor microenvironment
by: Anette Hauge, et al.
Published: (2020-05-01)

Antifibrotic therapy in chronic hepatitis C
by: Rinaldo Focaccia Siciliano, et al.

Hepatoprotective and Antifibrotic Effects of Indonesian Propolis
by: Diding Heri Prasetyo, et al.
Published: (2019-12-01)

Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience
by: Kodai Kawamura, et al.
Published: (2019-06-01)

A new antifibrotic target of Ac-SDKP: inhibition of myofibroblast differentiation in rat lung with silicosis.
by: Hong Xu, et al.
Published: (2012-01-01)